Benign prostatic hyperplasia: maximizing treatment with alpha blockers.
Lowenthal
D T
DT
VA Medical Center, Gainesville, FL, USA.
Flannery
M
M
Mader
S L
SL
Nelson
R P
RP
D000317:Adrenergic alpha-Antagonists / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D000368:Aged; D000369:Aged, 80 and over; D006801:Humans; D006973:Hypertension / Q000150:complications / Q000188:drug therapy; D007024:Hypotension, Orthostatic / Q000139:chemically induced* / Q000175:diagnosis / Q000453:epidemiology; D008297:Male; D008875:Middle Aged; D017430:Prostate-Specific Antigen / Q000097:blood; D011470:Prostatic Hyperplasia / Q000145:classification / Q000150:complications / Q000175:diagnosis / Q000188:drug therapy; D011471:Prostatic Neoplasms / Q000175:diagnosis; D013449:Sulfonamides / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D000077409:Tamsulosin; D014563:Urodynamics
D000317:Adrenergic alpha-Antagonists; D013449:Sulfonamides; D017430:Prostate-Specific Antigen; D000077409:Tamsulosin